First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis

被引：0
作者：
Naidoo, Kogieleum [1 ,2 ]
Perumal, Rubeshan [1 ,2 ]
机构：
[1] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa, ZA-4001 Durban, South Africa
[2] Univ KwaZulu Natal, MRC, CAPRISA HIV TB Pathogenesis & Treatment Res UnitZA, ZA-4001 Durban, South Africa
来源：
LANCET INFECTIOUS DISEASES | 2025年 / 25卷 / 04期
关键词：
D O I：
10.1016/S1473-3099(24)00653-4
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：366 / 367
页数：2
相关论文
共 10 条
  • [1] Dawson R, 2023, Antimicrob Agents Chemother, V67
  • [2] QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial
    Dooley, Kelly E.
    Rosenkranz, Susan L.
    Conradie, Francesca
    Moran, Laura
    Hafner, Richard
    Von Groote-Bidlingmaier, Florian
    Lama, Javier R.
    Shenje, Justin
    De los Rios, Jorge
    Comins, Kyla
    Morganroth, Joel
    Diacon, Andreas H.
    Cramer, Yoninah S.
    Donahue, Kathleen
    Maartens, Gary
    [J]. LANCET INFECTIOUS DISEASES, 2021, 21 (07) : 975 - 983
  • [3] Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
    Dorman, S. E.
    Nahid, P.
    Kurbatova, E., V
    Phillips, P. P. J.
    Bryant, K.
    Dooley, K. E.
    Engle, M.
    Goldberg, S., V
    Phan, H. T. T.
    Hakim, J.
    Johnson, J. L.
    Lourens, M.
    Martinson, N. A.
    Muzanyi, G.
    Narunsky, K.
    Nerette, S.
    Nguyen, N., V
    Pham, T. H.
    Pierre, S.
    Purfield, A. E.
    Samaneka, W.
    Savic, R. M.
    Sanne, I
    Scott, N. A.
    Shenje, J.
    Sizemore, E.
    Vernon, A.
    Waja, Z.
    Weiner, M.
    Swindells, S.
    Chaisson, R. E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (18) : 1705 - 1718
  • [4] OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor
    Hariguchi, Norimitsu
    Chen, Xiuhao
    Hayashi, Yohei
    Kawano, Yoshikazu
    Fujiwara, Mamoru
    Matsuba, Miki
    Shimizu, Hiroshi
    Ohba, Yoshio
    Nakamura, Izuru
    Kitamoto, Ryuki
    Shinohara, Toshio
    Uematsu, Yukitaka
    Ishikawa, Shunpei
    Itotani, Motohiro
    Haraguchi, Yoshikazu
    Takemura, Isao
    Matsumoto, Makoto
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (06)
  • [5] Advances in tuberculosis control during the past decade
    Naidoo, Kogieleum
    Perumal, Rubeshan
    [J]. LANCET RESPIRATORY MEDICINE, 2023, 11 (04) : 311 - 313
  • [6] Restocking the tuberculosis drug arsenal
    Nuermberger, Eric L.
    Chaisson, Richard E.
    [J]. NATURE MEDICINE, 2024, 30 (03) : 642 - 643
  • [7] Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis
    Perumal, Rubeshan
    Bionghi, Neda
    Nimmo, Camus
    Letsoalo, Marothi
    Cummings, Matthew J.
    Hopson, Madeleine
    Wolf, Allison
    Al Jubaer, Shamim
    Padayatchi, Nesri
    Naidoo, Kogieleum
    Larsen, Michelle H.
    O'Donnell, Max
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62 (06)
  • [8] Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis
    Poulton, Nicholas C.
    Azadian, Zachary A.
    DeJesus, Michael A.
    Rock, Jeremy M.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (09)
  • [9] The potential distraction of a pan-regimen approach to tuberculosis
    Rucsineanu, Oxana
    Furin, Jennifer
    [J]. LANCET GLOBAL HEALTH, 2024, 12 (10): : e1565 - e1566
  • [10] Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study
    Ryckman, Theresa S.
    McQuaid, C. Finn
    Cohen, Ted
    Menzies, Nicolas A.
    Kendall, Emily A.
    [J]. LANCET GLOBAL HEALTH, 2024, 12 (10): : e1629 - e1637
1